Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ Brushes Off Vaccine Criticism, Awaits US Readout

WHO Endorsement Counters Fears

Executive Summary

While fast-developing news on COVID-19 is grabbing the headlines, oncology will continue to drive growth in 2021.

You may also be interested in...



After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact

The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.

AZ's Alexion Acquisition Looks Astute Bit Of Business

Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.

Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans

GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel